vs
Nerdy Inc.（NRDY）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Nerdy Inc.的季度营收约是REGENXBIO Inc.的1.6倍（$49.1M vs $30.3M），Nerdy Inc.净利率更高（-18.8% vs -221.3%，领先202.5%），REGENXBIO Inc.同比增速更快（43.0% vs 2.3%），Nerdy Inc.自由现金流更多（$-4.3M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -4.4%）
Nerdy Inc.是总部位于美国的知名教育科技企业，旗下运营Varsity Tutors等在线学习平台，提供一对一实时辅导、点播课程、备考资源及技能培训内容，服务K12学生、高校学习者及职场人士，覆盖多类学业与职业能力提升需求。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
NRDY vs RGNX — 直观对比
营收规模更大
NRDY
是对方的1.6倍
$30.3M
营收增速更快
RGNX
高出40.7%
2.3%
净利率更高
NRDY
高出202.5%
-221.3%
自由现金流更多
NRDY
多$48.5M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-4.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $49.1M | $30.3M |
| 净利润 | $-9.2M | $-67.1M |
| 毛利率 | 51.0% | — |
| 营业利润率 | -28.3% | -190.0% |
| 净利率 | -18.8% | -221.3% |
| 营收同比 | 2.3% | 43.0% |
| 净利润同比 | 8.9% | -31.2% |
| 每股收益（稀释后） | $-0.07 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NRDYRGNX
| Q4 25 | $49.1M | $30.3M | ||
| Q3 25 | $37.0M | $29.7M | ||
| Q2 25 | $45.3M | $21.4M | ||
| Q1 25 | $47.6M | $89.0M | ||
| Q4 24 | $48.0M | $21.2M | ||
| Q3 24 | $37.5M | $24.2M | ||
| Q2 24 | $51.0M | $22.3M | ||
| Q1 24 | $53.7M | $15.6M |
净利润NRDYRGNX
| Q4 25 | $-9.2M | $-67.1M | ||
| Q3 25 | $-12.3M | $-61.9M | ||
| Q2 25 | $-7.9M | $-70.9M | ||
| Q1 25 | $-10.5M | $6.1M | ||
| Q4 24 | $-10.1M | $-51.2M | ||
| Q3 24 | $-15.9M | $-59.6M | ||
| Q2 24 | $-9.1M | $-53.0M | ||
| Q1 24 | $-7.4M | $-63.3M |
毛利率NRDYRGNX
| Q4 25 | 51.0% | — | ||
| Q3 25 | 62.9% | — | ||
| Q2 25 | 61.5% | — | ||
| Q1 25 | 58.0% | — | ||
| Q4 24 | 66.6% | 70.2% | ||
| Q3 24 | 70.5% | 48.8% | ||
| Q2 24 | 65.7% | 52.5% | ||
| Q1 24 | 68.0% | 72.6% |
营业利润率NRDYRGNX
| Q4 25 | -28.3% | -190.0% | ||
| Q3 25 | -51.5% | -176.3% | ||
| Q2 25 | -27.1% | -296.3% | ||
| Q1 25 | -34.8% | 13.6% | ||
| Q4 24 | -34.0% | -242.1% | ||
| Q3 24 | -68.5% | -256.6% | ||
| Q2 24 | -29.9% | -251.3% | ||
| Q1 24 | -23.9% | -408.8% |
净利率NRDYRGNX
| Q4 25 | -18.8% | -221.3% | ||
| Q3 25 | -33.2% | -208.3% | ||
| Q2 25 | -17.4% | -331.8% | ||
| Q1 25 | -22.1% | 6.8% | ||
| Q4 24 | -21.1% | -241.3% | ||
| Q3 24 | -42.4% | -246.3% | ||
| Q2 24 | -17.8% | -237.7% | ||
| Q1 24 | -13.9% | -405.4% |
每股收益（稀释后）NRDYRGNX
| Q4 25 | $-0.07 | $-1.30 | ||
| Q3 25 | $-0.10 | $-1.20 | ||
| Q2 25 | $-0.07 | $-1.38 | ||
| Q1 25 | $-0.09 | $0.12 | ||
| Q4 24 | $-0.09 | $-0.99 | ||
| Q3 24 | $-0.14 | $-1.17 | ||
| Q2 24 | $-0.08 | $-1.05 | ||
| Q1 24 | $-0.07 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $47.9M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $19.0M | $102.7M |
| 总资产 | $76.2M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NRDYRGNX
| Q4 25 | $47.9M | $230.1M | ||
| Q3 25 | $32.7M | $274.2M | ||
| Q2 25 | $36.7M | $323.3M | ||
| Q1 25 | $44.9M | $267.9M | ||
| Q4 24 | $52.5M | $234.7M | ||
| Q3 24 | $65.0M | $255.5M | ||
| Q2 24 | $69.8M | $290.4M | ||
| Q1 24 | $77.0M | $338.7M |
股东权益NRDYRGNX
| Q4 25 | $19.0M | $102.7M | ||
| Q3 25 | $24.3M | $161.5M | ||
| Q2 25 | $31.8M | $213.7M | ||
| Q1 25 | $34.4M | $274.2M | ||
| Q4 24 | $39.5M | $259.7M | ||
| Q3 24 | $43.3M | $301.4M | ||
| Q2 24 | $52.2M | $348.3M | ||
| Q1 24 | $52.8M | $390.7M |
总资产NRDYRGNX
| Q4 25 | $76.2M | $453.0M | ||
| Q3 25 | $70.4M | $525.2M | ||
| Q2 25 | $73.7M | $581.0M | ||
| Q1 25 | $83.0M | $490.9M | ||
| Q4 24 | $92.5M | $466.0M | ||
| Q3 24 | $106.8M | $519.1M | ||
| Q2 24 | $111.3M | $569.4M | ||
| Q1 24 | $121.3M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.9M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-4.3M | $-52.8M |
| 自由现金流率自由现金流/营收 | -8.7% | -174.0% |
| 资本支出强度资本支出/营收 | 2.7% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-24.2M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流NRDYRGNX
| Q4 25 | $-2.9M | $-52.3M | ||
| Q3 25 | $-2.4M | $-56.0M | ||
| Q2 25 | $-7.0M | $-49.3M | ||
| Q1 25 | $-6.4M | $33.6M | ||
| Q4 24 | $-11.3M | $-31.6M | ||
| Q3 24 | $-3.1M | $-40.5M | ||
| Q2 24 | $-5.6M | $-45.5M | ||
| Q1 24 | $4.4M | $-55.5M |
自由现金流NRDYRGNX
| Q4 25 | $-4.3M | $-52.8M | ||
| Q3 25 | $-4.1M | $-56.5M | ||
| Q2 25 | $-8.2M | $-49.7M | ||
| Q1 25 | $-7.6M | $32.6M | ||
| Q4 24 | $-12.5M | $-32.7M | ||
| Q3 24 | $-5.0M | $-40.9M | ||
| Q2 24 | $-7.1M | $-46.0M | ||
| Q1 24 | $2.1M | $-56.0M |
自由现金流率NRDYRGNX
| Q4 25 | -8.7% | -174.0% | ||
| Q3 25 | -11.2% | -189.9% | ||
| Q2 25 | -18.1% | -232.8% | ||
| Q1 25 | -16.0% | 36.6% | ||
| Q4 24 | -26.0% | -154.2% | ||
| Q3 24 | -13.3% | -168.9% | ||
| Q2 24 | -14.0% | -206.2% | ||
| Q1 24 | 4.0% | -358.5% |
资本支出强度NRDYRGNX
| Q4 25 | 2.7% | 1.7% | ||
| Q3 25 | 4.6% | 1.7% | ||
| Q2 25 | 2.6% | 1.8% | ||
| Q1 25 | 2.5% | 1.2% | ||
| Q4 24 | 2.4% | 5.1% | ||
| Q3 24 | 5.2% | 1.3% | ||
| Q2 24 | 3.0% | 2.1% | ||
| Q1 24 | 4.1% | 3.6% |
现金转化率NRDYRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NRDY
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
